These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 20011529)

  • 41. Falciparum malaria fully cleared by amodiaquine, pyrimethamine-sulfadoxine and pyrimethamine-sulfalene in areas of chloroquine resistance in Dodoma, Tanzania.
    Irare SG; Lemnge MM; Mhina JI
    Trop Geogr Med; 1991 Oct; 43(4):352-6. PubMed ID: 1812599
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Change of antimalarial first-line treatment in Burkina Faso in 2005].
    Gansané A; Nébié I; Soulama I; Tiono A; Diarra A; Konaté AT; Ouédraogo A; Sirima BS
    Bull Soc Pathol Exot; 2009 Feb; 102(1):31-5. PubMed ID: 19343918
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Usefulness of day 7 lumefantrine plasma concentration as a predictor of malaria treatment outcome in under-fives children treated with artemether-lumefantrine in Tanzania.
    Kilonzi M; Minzi O; Mutagonda R; Baraka V; Sasi P; Aklillu E; Kamuhabwa A
    Malar J; 2020 Feb; 19(1):66. PubMed ID: 32046718
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Residual antimalarial concentrations before treatment in patients with malaria from Cambodia: indication of drug pressure.
    Hodel EM; Genton B; Zanolari B; Mercier T; Duong S; Beck HP; Olliaro P; Decosterd LA; Ariey F
    J Infect Dis; 2010 Oct; 202(7):1088-94. PubMed ID: 20726764
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Malaria Surveillance - United States, 2015.
    Mace KE; Arguin PM; Tan KR
    MMWR Surveill Summ; 2018 May; 67(7):1-28. PubMed ID: 29723168
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Individual, facility and policy level influences on national coverage estimates for intermittent preventive treatment of malaria in pregnancy in Tanzania.
    Marchant T; Nathan R; Jones C; Mponda H; Bruce J; Sedekia Y; Schellenberg J; Mshinda H; Hanson K
    Malar J; 2008 Dec; 7():260. PubMed ID: 19094198
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of intermittent preventive treatment of malaria in pregnancy with dihydroartemisinin-piperaquine versus sulfadoxine-pyrimethamine on the incidence of malaria in infancy: a randomized controlled trial.
    Kakuru A; Jagannathan P; Kajubi R; Ochieng T; Ochokoru H; Nakalembe M; Clark TD; Ruel T; Staedke SG; Chandramohan D; Havlir DV; Kamya MR; Dorsey G
    BMC Med; 2020 Aug; 18(1):207. PubMed ID: 32772921
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of the application of national malaria treatment guidelines in private pharmacies in a rural area in the Democratic Republic of Congo.
    Mandoko PN; Mbongi DM; Mumba DN; Bi Shamamba SK; Tshilolo LM; Muyembe JJ; Parzy D; Sinou V
    Med Sante Trop; 2019 Nov; 29(4):392-398. PubMed ID: 31884993
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Monitoring the efficacy of antimalarial medicines in India via sentinel sites: Outcomes and risk factors for treatment failure.
    Mishra N; Srivastava B; Bharti RS; Rana R; Kaitholia K; Anvikar AR; Das MK; Ghosh SK; Bhatt RM; Tyagi PK; Dev V; Phookan S; Wattal SL; Sonal GS; Dhariwal AC; Valecha N
    J Vector Borne Dis; 2016; 53(2):168-78. PubMed ID: 27353588
    [TBL] [Abstract][Full Text] [Related]  

  • 50. How sulfadoxine-pyrimethamine (SP) was perceived in some rural communities after phasing out chloroquine (CQ) as a first-line drug for uncomplicated malaria in Tanzania: lessons to learn towards moving from monotherapy to fixed combination therapy.
    Nsimba SE
    J Ethnobiol Ethnomed; 2006 Jan; 2():5. PubMed ID: 16403225
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Geographic differences in antimalarial drug efficacy in Uganda are explained by differences in endemicity and not by known molecular markers of drug resistance.
    Francis D; Nsobya SL; Talisuna A; Yeka A; Kamya MR; Machekano R; Dokomajilar C; Rosenthal PJ; Dorsey G
    J Infect Dis; 2006 Apr; 193(7):978-86. PubMed ID: 16518760
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial.
    Zongo I; Dorsey G; Rouamba N; Tinto H; Dokomajilar C; Guiguemde RT; Rosenthal PJ; Ouedraogo JB
    Lancet; 2007 Feb; 369(9560):491-8. PubMed ID: 17292769
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adverse birth outcomes among mothers who received intermittent preventive treatment with Sulphadoxine-Pyrimethamine in the low malaria transmission region.
    Mikomangwa WP; Oms M; Aklillu E; Kamuhabwa AAR
    BMC Pregnancy Childbirth; 2019 Jul; 19(1):236. PubMed ID: 31286878
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Therapeutic efficacy of sulfadoxine-pyrimethamine and prevalence of resistance markers in Tanzania prior to revision of malaria treatment policy: Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase mutations in monitoring in vivo resistance.
    Mugittu K; Ndejembi M; Malisa A; Lemnge M; Premji Z; Mwita A; Nkya W; Kataraihya J; Abdulla S; Beck HP; Mshinda H
    Am J Trop Med Hyg; 2004 Dec; 71(6):696-702. PubMed ID: 15642957
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vivo efficacy study of amodiaquine and sulfadoxine/ pyrimethamine in Kibwezi, Kenya and Kigoma, Tanzania.
    Gorissen E; Ashruf G; Lamboo M; Bennebroek J; Gikunda S; Mbaruku G; Kager PA
    Trop Med Int Health; 2000 Jun; 5(6):459-63. PubMed ID: 10929148
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of sulfadoxine-pyrimethamine in chloroquine resistant falciparum malaria in Bombay.
    Garg MR; Gogtay NJ; Kshirsagar NA
    J Assoc Physicians India; 1996 Oct; 44(10):683-5. PubMed ID: 9251339
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Decreased availability of antimalarials in the private sector following the policy change from chloroquine to sulphadoxine-pyrimethamine in the Kilombero Valley, Tanzania.
    Hetzel MW; Msechu JJ; Goodman C; Lengeler C; Obrist B; Kachur SP; Makemba A; Nathan R; Schulze A; Mshinda H
    Malar J; 2006 Nov; 5():109. PubMed ID: 17105662
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Risk factors for placental malaria and associated adverse pregnancy outcomes in Rufiji, Tanzania: a hospital based cross sectional study.
    Ndeserua R; Juma A; Mosha D; Chilongola J
    Afr Health Sci; 2015 Sep; 15(3):810-8. PubMed ID: 26957969
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical and molecular monitoring of Plasmodium falciparum resistance to antimalarial drug (artesunate+sulphadoxine-pyrimethamine) in two highly malarious district of Madhya Pradesh, Central India from 2012-2014.
    Mishra S; Bharti PK; Shukla MM; Ali NA; Kashyotia SS; Kumar A; Dhariwal AC; Singh N
    Pathog Glob Health; 2017 Jun; 111(4):186-194. PubMed ID: 28549390
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Determinants of treatment response to sulfadoxine-pyrimethamine and subsequent transmission potential in falciparum malaria.
    Méndez F; Muñoz A; Carrasquilla G; Jurado D; Arévalo-Herrera M; Cortese JF; Plowe CV
    Am J Epidemiol; 2002 Aug; 156(3):230-8. PubMed ID: 12142257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.